Catalyst Event

Johnson & Johnson (JNJ) · Other

From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)

4/27/2026, 12:00:00 AM

OtherSentiment: Positive

Announced the U.S. FDA has granted Priority Review for the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA).

Korean Translation

미국 FDA가 온난 자가면역 용혈성 빈혈(wAIHA) 치료를 위한 이마비(IMAAVY®, nipocalimab-aahu)의 보충 바이오의약품 품목 허가 신청(sBLA)에 대해 우선 심사 자격을 부여했다고 발표함.

Related Recent Events

View Full Timeline